CMS Announces Sickle Cell Disease as Initial Focus of Cell and Gene Therapy (CGT) Access Model
On January 30, the Centers for Medicare & Medicaid Services (CMS) announced that sickle cell disease will be the first focus of the Cell and Gene Therapy (CGT) Access Model. The CGT Access Model is targeted to people with Medicaid living with rare and severe diseases by increasing their access to potentially life-changing treatments. Sickle cell disease is an extremely painful condition that disproportionately impacts Black Americans and has had limited treatment options.